Impact of Metformin, Statin, Aspirin and Insulin on the Prognosis of Unresectable Hcc Patients Receiving First-Line Lenvatinib or Atezolizumab plus Bevacizumab

AuthID
P-00Z-QR4
20
Author(s)
Rimini, M
·
Amadeo, E
·
Vitiello, F
·
Foti, S
·
Tada, T
·
Suda, G
·
Shimose, S
·
Kudo, M
·
Cheon, J
·
Lim, HY
·
Piscaglia, F
·
Yoo, C
·
Lonardi, S
·
Rossari, F
·
Camera, S
·
Gardini, AC
·
Presa, J
Document Type
Abstract
Year published
2023
Published
in ANNALS OF ONCOLOGY, ISSN: 0923-7534
Volume: 34, Pages: S1548-S1548 (1)
Conference
Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: DEC 01-03, 2023, Location: SINGAPORE
Indexing
Publication Identifiers
Wos: WOS:001122475400191
Source Identifiers
ISSN: 0923-7534
Export Publication Metadata
Marked List
Info
At this moment we don't have any links to full text documens.